GE Achieves Record Transmission of Power on a Super Energy Highway in India
14.11.2019 14:59:00 EET | Business Wire | Press release
GE’s Grid Solutions business (NYSE:GE) announced today a new milestone in its Champa-Kurukshetra ultra-high-voltage direct current (UHVDC) project in India with the 1,305-km link now capable of transmitting 4,500 MW of electricity. This follows the recent successful energization of the third of four poles planned for the ±800kV UHVDC transmission line.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191114005360/en/
Inside the Valve Hall of the Champa-Kurukshetra HVDC Converter Station, image courtesy of GE (Photo: Business Wire)
A special feature of the Champa project is the use of an overhead line with dedicated metallic return, which uses a neutral conductor as a part of the DC circuit. GE is the first company in the world to demonstrate this technology with this project and is therefore providing additional value to the customer by eliminating the typical technical and environmental issues associated with the traditional electrode solution.
The transmission line is a crucial component of the Indian government’s electricity-for-all initiative and will help provide reliable electricity for millions of people living in the states of Punjab, Haryana, Delhi, Uttar Pradesh and surrounding areas. The project is being executed by GE T&D India Limited, the listed entity of GE’s Grid Solutions business in India.
New government initiatives and robust private-sector investments have reversed India’s longstanding power deficit. With the growing renewable energy market, the nation now boasts an installed capacity of over 360 gigawatts (GW), making it the third-largest electricity producer in the world. However, to meet the government’s vision of power-to-all and to ensure last mile connectivity, continuous development of a robust transmission network is vital for the country.
Power Grid Corporation of India Ltd (POWERGRID), India’s largest state-owned transmission company, is helping address this issue by connecting the power deficit northern Indian region with power surplus regions of eastern India using GE’s UHVDC technology.
“Thanks to this latest milestone in the GE Champa-Kurukshetra project, India is now transmitting more electricity over this link than any other DC link in India, helping to resolve the supply shortfalls in the north. This project also includes an integration where two separately designed bi-poles are running in parallel operation over the same DC transmission line, a design feature only seen on two other HVDC projects in the world, both of which GE was involved with, a great compliment to our legacy and current HVDC controls capability. On behalf of everyone at GE’s Grid Solutions, I would like to thank our teams in India and our UK HVDC center of excellence for this remarkable feat,” said Rajendra Iyer, head of Grid Integrated Solutions at GE’s Grid Solutions. The Grid Integration Solutions division, comprised of High Voltage Direct Current (HVDC) and FACTS technologies, designs and integrates transmission solutions that help meet the world’s ever-evolving power needs.
The Champa-Kurukshetra project transmits electricity from power generating plants located across Chhattisgarh, a state in eastern region of India, to a GE-built rectifier station in Champa, where it is converted from alternating current (AC) to direct current (DC). The electricity is transported in bulk across the UHVDC line and is then converted back to AC by a GE inverter station in Kurukshetra, Haryana. From there, power is transported to the surrounding rural states who are in need of reliable and consistent electrical power. DC technology efficiently moves electricity over long distances which lowers transmission costs and losses. Additionally, it is a more environment-friendly technology because it requires fewer overhead lines to deliver the same amount of power as a high-voltage AC system.
Phase 1 of the project, completed in 2017, provided 3,000 MW of transmission capacity. GE’s recent energization of Pole 3 added another 1,500 MW of transmission capacity, marking a key benchmark towards the completion of Phase 2. Once Pole 4 is commissioned, the entire system will transmit 6,000 MW of electricity at 800kV - making the project one of the largest generation-to-consumption transmission systems in the world.
Notes to Editors:
About GE T&D India Limited:
GE T&D is the listed entity of GE’s Grid Solutions business in India. With over 100 years of presence in India, GE T&D India is a leading player in the Power Transmission & Distribution business with a product portfolio ranging from Medium Voltage to Ultra High Voltage (1,200 kilovolt) for Power Generation, Transmission and Distribution, Industry and Infrastructure markets.
GE T&D India has a significant presence in all stages of the power supply chain and offers a wide range of products that include Power Transformers, Circuit Breakers, Gas Insulated Switchgears, Instrument Transformers, Substation Automation Equipment. Digital Software Solutions, Turnkey Solutions for Substation Engineering & Construction, Flexible AC Transmission Systems, High Voltage DC & Services suite of offerings. With six manufacturing sites, GE T&D India is future ready to meet the growing demands for equipment and services. GE is focused towards on introducing Green and Digital Solutions aimed towards making the Indian Grid smarter and more environmentally-friendly.
About GE’s Grid Solutions:
Grid Solutions, a GE Renewable Energy business, serves customers globally with over 17,000 employees in approximately 80 countries. Grid Solutions helps enable utilities and industry to effectively manage electricity from the point of generation to the point of consumption, helping to maximize the reliability, efficiency and resilience of the grid. For more about GE Renewable Energy’s Grid Solutions business, visit www.gegridsolutions.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191114005360/en/
Contact information
For media queries, please contact:
Anshul Madaan
Communications Leader
GE Grid Solutions – South Asia
anshul.madaan@ge.com
Allison J. Cohen
GE Renewable Energy, Grid Solutions business
External Communications Manager
+972-(0)54-7299742
allison.j.cohen@ge.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
